CA2327730A1 - Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger - Google Patents
Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger Download PDFInfo
- Publication number
- CA2327730A1 CA2327730A1 CA002327730A CA2327730A CA2327730A1 CA 2327730 A1 CA2327730 A1 CA 2327730A1 CA 002327730 A CA002327730 A CA 002327730A CA 2327730 A CA2327730 A CA 2327730A CA 2327730 A1 CA2327730 A1 CA 2327730A1
- Authority
- CA
- Canada
- Prior art keywords
- fumarate
- molecular weight
- poly
- polydispersity index
- average molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/52—Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
- C08G63/56—Polyesters derived from ester-forming derivatives of polycarboxylic acids or of polyhydroxy compounds other than from esters thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
- A61L24/0084—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/52—Polycarboxylic acids or polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
Abstract
High molecular weight linear poly(propylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate and a method for making same. Fumaryl chloride and propylene glycol are reacted in the presence of potassium carbonate. The potassium carbonate present in the reaction solution prevents the acid by-product from catalyzing reactions at the fumarate double bond. The bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF). The P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.
Description
.1789-02302 - . ~ .. .,u~
IPE~i ~,;~_.~ 5 ~I a V 1,~9' SYNTHESIS OF POLYPROPYLENE FL;m~IARATE) BY ACYLATION OF PROPYLENE GLYCOL
IN THE PRESENCE OF A PROTON SCAVENGER
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of provisional applications Serial No.
60/081,308, filed April 10, 1998 and entitled Synthesis of Poly(Proplyene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger; Serial No. 60/082,182, filed April 16, 1998 and entitled In Vivo Degradation of a Poly(Propylene Fumarate)l ~
Tricalcium. Phosphate Injectable Composite Scaffold; and Serial No.
60/081,405, filed April 10, 1998 and entitled Crosslinking Characteristics of an !nl~ctable Poly(Propylene Fumarate)1~3T'ricalcium Phosphate Past and Mechanical Properties of the Crosslinked Composite for Use as a Biodegradable Bone Cement.
STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT
This work was funded by the National Institutes of Health (RO1-AR44381) (AGM), the National Science Foundation (PSE), and National Institutes of Health Biotechnology Training Grant ST32GM08362.
TECHNICAL FIELD OF THE INVENTION
This invention relates to methods for the synthesis of high molecular weight forms of polypropylene fumarate) having a relatively low polydispersity index. More particularly, the present invention provides methods for synthesizing polypropylene fumarate) having molecular weights above 4,000 and polydispersity indices below 2, and more particularly below 1.8, wherein the high molecular weight polypropylene fumarate) is synthesized in the presence of a proton scavenger.
BACKGROUND OF THE INVENTION
It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bune has been broken or has been resected as a result of a bone tumor.
In these instances, the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself. Often these implants comprise biodegradable compounds or parts made from such compounds. For example, it is known to provide porous, biodegradable compounds that contain or are coated with an osteogenic substance. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment.
For obvious reasons, implants, regardless of whether they are biodegradable, should be biocompatible and non-toxic. Furthermore, the steps required for implantation of the implant (eg. the application or generation of heat and the generation of chemical by-products) should also be biocompatible and non-toxic. Also, the techniques and time periods required for implantation should be suited to the surgical environment.
Under current practices, bone implants are typically formed from a substance that is initially malleable and then becomes hard after a reasonably short period of time. Because living bone tends to atrophy and degrade in the absence of compressive stress, however, it is important that the implant not become too hard. An implant whose compressive strength is too great (i.e. an implant that is too hard) will cause stress shielding of the surrounding bone.
Stress shielding in taro causes the surrounding bone to weaken and may ultimately result in catastrophic failure. Hence, the suitability of a given substance for implantation as a bone replacement depends on its biocompatibility, set time, biodegradability and ultimate compressive strength. Certain polymers have been found to be suitable in this regard.
Polypropylene fumarate) (hereinafter "P(PF)'~ is one such substance. P(PF) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are cleared from the human body by normal metabolic processes. Although P(PF) is a known polymer, its routine, reproducible synthesis and the synthesis of high molecular weight forms and forms with low polydispersity indices have not previously been successfully accomplished. Known methods for the synthesis of P(PF), for example by equilibrium polycondensation, utilize reactions that are difficult to control. These synthetic methods typically require extremely high heat, the presence of a catalyst, and/or long reaction times.
Nevertheless, the fumarate double bonds in P(PF) are reactive and crosslink at low temperatures, making it valuable as an in situ polymerizable biomaterial. An effective composite mixture incorporating P(PF), a crosslinking monomer (N vinyl pyrrolidinone), a porogen (sodium chloride), and a particulate phase ((3-tricalcium phosphate) can be injected into skeletal defects of irregular shape or size. As is known in the art, the mechanical properties of the cured material can be tailored by altering the ratios of the porogen and particulate phase, as well as the monomer to polymer ratio.
The maximum molecular weight MW of the P(PF) polymer that has heretofore been reasonably achievable without encountering an unacceptably high polydispersity index is limited to less than 3,000. P(PF) polymers have been produced having MW above 3,000, but because the degree of cross-linking varies greatly within the specimen, the polydispersity indices, (the ratio of weight average molecular weight to number average molecular weight), for these polymers are well above 2Ø Premature crosslinking of the polymer often limits the linear size or molecular weight of the linear polymer that can be achieved. It is believed that this is in part due to the fact that some of the fumarate double bonds are reaction sites for the acid-catalyzed addition of various other groups. The presence of these groups and the corresponding elimination of the double bond reduces the degree of unsaturation and thus limits molecular weight. Early attempts to mitigate this effect and increase the weight average molecular weight entailed the use of an amine to neutralize the acid, but results of this reaction were undesirable. Other early attempts included the use of buffers, and several other materials also proved ineffective.
Hence, it is highly desirable to provide an efficient, controlled synthetic reaction whereby high molecular weight linear polypropylene fumarate) having a relatively low polydispersity index can reproducibly synthesized without regardless of whether an acid catalyst is used.
BRIEF SLrMMARY OF THE INVENTION
The present invention provides a method for making high molecular weight linear poiy(pmpylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate. According to the present invention, fumaryi chloride and propylene glycol are reacted in the presence of potassium carbonate, which serves as a proton scavenger, to produce bis(propyl fumarate). The reaction of fumaryl chloride and propylene glycol also produces HCI. The potassium carbonate present in the reaction solution reacts with the HCI
to give water and COZ and prevents the acid from catalyzing reactions at the fumarate double bond. According to a prefer ed embodiment, a mole ratio of KZCO, to fumaryl chloride of between approximately 1.2:1 and 3:1 is used. The bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF).
The P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.
BRIEF DESCRIPTION OF THE DRAWINGS
For an introduction to the detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying Figures, wherein:
Figure 1 is a labeled chemical structure of polypropylene fiunarate);
Figure 2 is a two-step reaction scheme for the formation of polypropylene fumarate) from propylene glycol and fumaryl chloride;
Figure 3 is an FTIR spectra of polypropylene fumarate) following transesterification and of the short chain oligomer prior to transesterification; and Figures 4A-C are a series of NMR spectra confirming the structure illustrated in Figure 1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It has been discovered that the P(PF)s formed according to the preferred embodiment have greater molecular weights than those produced by previously known reaction methods without requiring the use of a catalyst. Equally importantly, the preferred method yields P(PF)s having polydispersity indices, or PI (PI = Mw / M" where MW is the weight average molecular weight and Mn is the number average molecular weight), less than 2 and more preferably approximately 1.
Referring initially to Figure 1, the chemical structure for the desired reaction product P(PF) is shown and various functional groups are labeled 1-6. The structure depicted in Figure 1 is confirmed by the peaks labeled correspondingly 1-6 in Figures 4A-C, as described in detail below. According to the present invention, P(PF)" for which n equals at least 10 and more preferably at least 14, can be manufactured consistently and with a relatively high polydispersity index in a two-step process. The first step includes acylation of propylene glycol with fumaryl chloride in the presence of a proton scavenger. As generally disclosed in U.S. Patent 5,733,951, which is incorporated herein in its entirety, the acylation step releases 2HCl, which results in a lowering of the pH of the reaction solution. In prior art processes, the presence of the acid allowed the acid-catalyzed addition of various other groups, such as excess propylene glycol, at the fumarate double bond. These undesired side reactions reduced the purity of the desired bis(propyl fumarate) intermediate and thus increased the polydispersity index and reduced the maximum molecular weight of the ultimate P(PF) product that can be obtained.
It has been discovered that the addition of potassium carbonate to the reaction solution effectively neutralizes the acid and prevents premature loss of the fumarate double bond. The 5 potassium carbonate is preferably added in molar excess, to ensure that the acid catalysis of bonding across the double bonds is minimized. This process produces a low molecular weight oligomer, bis(propyl fumarate), which can then be transesterified according to lc~own techniques.
As shown in Figure 2, the formation of PPF is a two-step reaction process. The first step involves forming a short chain oligomer from fumaryl chloride and propylene glycol in the presence of potassium carbonate. This is followed by a transesterifieation step to form the high molecular weight polymer, PPF. The specifics of each reaction are described below.
Ezample 1 Materials Fumaryl chloride (Acros, Pittsburgh, PA) was purified by distillation at 159-161 °C. Propylene glycol was also obtained from Acros and used as received. Anhydrous potassium carbonate (Fisher, Pittsburgh, PA) was ground into a fine powder with a mortar and pestle. The solvents for polymer purification were purchased from Fisher as reagent grade and used as received.
Oligomer preparation. Fumaryl chloride, propylene glycol, and potassium carbonate were measured out in a 1:3:1.5 molar ratio. The propylene glycol was dissolved in chloroform (1:2 by volume) and placed in a 2 L-3 neck flask along with the powdered potassium carbonate.
This mixture was stirred with an overhead mechanical stirrer to form a slurry.
Fumaryl chloride dissolved in chloroform ( 1:1 volume ratio) was added dropwise to the slurry. The reaction mixture was maintained at room temperature (by altering the rate of the fumaryl chloride addition) under a nitrogen blanket. Additional chloroform was added as needed to facilitate stirring. Upon completion of the fumaryl chloride addition, the mixture was transferred to 50 mL centrifuge tubes and spun down for 15 minutes at 4000 rpm until the potassium carbonate was completely removed. The supernatant was then added dropwise to petroleum ether to force the oligomer out of solution, and the precipitate was rotary-evaporated to yield an amber-colored oil.
Transesterification. The oligomer was transferred to a 1 L-3 neck reaction vessel suspended in an oil bath. The bath temperature was raised to 160°C and the system was evacuated to a pressure of 100-110 mm Hg. Nitrogen was passed through a coil in the oil bath for preheating and subsequently bubbled into the bottom of the reaction vessel to facilitate mixing and maintain an inert environment. Propylene glycol was liberated by the formation of each O-CO bond during the transesterification and was condensed as a byproduct.
Samples for kinetic analysis of the molecular weight progression were removed each hour during the reaction. Upon termination of the transesterification, the vessel was pressurized to 1 arm and the product was allowed to cool. This product was dissolved in chloroform and precipitated through dropwise addition of the mixture to petroleum ether with stirring. The precipitate was rotary-evaporated for 2 hours. The final product, PPF, was a much darker color and of a greater viscosity when compared to PPF synthesized in the absence of potassium carbonate. Moreover, the transesterification reaction no longer catalytic antimony trioxide, an undesirable compound for in vivo applications. For the polymer characterization described below, PPF prepared fiom a 16 hour transesterification with a number average molecular weight of approximately 5000 Da was used.
Polymer Characterization.
FTTR Fourier transform infrared spectra were obtained on a Nicolet 500 spectrometer (Madison, W17. Samples were placed on a zinc selenide attenuated total reflection crystal for analysis. A total of 32 scans was collected at a 4 crri' resolution. The peak at 2300 crri ' is due to the presence of carbon dioxide in the sampling chamber.
NMR Nuclear magnetic resonance spectra were obtained on a Broker 500 MHz spectrometer (Switzerland). 'H, Distortionless Enhancement by Polarization Transfer-135 "C
(DEPT-135 "C), and 2D 'H-"C chemical shift correlation spectra of PPF were acquired using standard pulse programs.
MS Mass spectral data of the oligomer and high molecular weight polymer were obtained in fast-atom bombardment (FAB) mode on a Finnigan MAT 95 spectrometer (New York, NY) using a Cs ion gun. Nitrobenzyl alcohol was used as a matrix.
GPC Gel permeation chromatography was used to determine polymer molecular weight distributions through the application of a differential refractometer detector (Waters, Model 410, Milford, MA). A Phenogel guard column (50x7.8 mm, 5 gym, mixed bed, Phenomenex, Tomance, CA) and a Phenogel column (300x7.8 mm, S~m, mixed bed, Phenomenex) were used to elute the samples at 1 mL,/min chloroform flow rate. Polystyrene standards were used to obtain a calibration curve for calculating the polymer molecular weights.
Samples were analyzed for four transesterification reactions, each spanning a 16 hour time fi~ame.
Results FTIR Carbonyl stretching at 1714 ctrl', C=C stretching at 1640 cm'', and methylene scissoring and asymmetric bending at 1457 cm' were all evident in the FTIR
spectra of the oligomer and final polymer (Figure 3). C-O stretching at 1266 ctrl', methyl symmetric bending at 1382 crri', and the C-H bend of the double bond at 983 crri' were also present in both spectra. The oligomer had a more intense OH stretch at 3340 ciri' than the higher molecular weight polymer due to the greater number of hydroxyl end groups in the short chain oligomer. The relative intensity of the hydroxyl peak decreased with increasing molecular weight of the samples taken throughout the transesterificadon. No major differences were identified in the FTIR spectra of the PPF formed through the new reaction pathway as opposed to the previous method.
NMR Through the combination of proton, carbon, and two-dimensional proton-carbon chemical shift correlation spectra, the PPF chemical structure represented in Figure 1 was verified. Contour positions for all pertinent functional groups represented in this structure are given in Table 1 and shown in Figures 4(a)-(c).
Table 1. Identification of Functional Group Contours From the 2-d Proton-Carbon Correlation NMR Spectra.
Functional Figure LabelProton (ppm)Carbon (ppm)DEPT Peak Group Propyl methyl 1 1.15-1.51 16.05-19.4 Methyl Propyl methine2 4.08-4.11 65.2 Methine of 2 alcohol Pmpyl methylene3 4.03-4.17 69.8-70.1 Methylene of 2 alcohol Olefinic bonds4 6.85-6.93 132.9-134.4no contour propyl methine5 5.0-5.12 72.4-73.1 Methine of 1 alcohol propyl methylene6 3.57-3.69 64.7 Methyiene of 1 alcohol not shown - 165.0-171.8no contour The peak assignments are based on calculated proton and carbon chemical shifts found from the tabulated values in Silverstein et al.~~ Acylation of propylene glycol to leave a primary alcohol resulted in a methylene peak (6) with signals at 'H 3.57-3.69 and "C
64.7 and a methine peak (5) with signals at'H 5.0-5.12 and "C 72.4-73.1. Acylation of propylene glycol to leave a secondary alcohol resulted in a methylene peak (3) with signals at'H 4.03-4.17 and "C 69.8-70.1 and a methine peak (2) with signals at 'H 4.08-4.1 l and "C 65.2.
The spectra of the short chain oligomer and the higher molecular weight polymer were investigated to confirm these peak assignments. The secondary alcohol methylene (3) and primary alcohol methine (5) each produced two signals. The signals within each pair were of approximately the same intensity in the oligomer spectrum. However, in the high molecular weight polymer spectrum, one signal from each pair was more intense. The weaker of the two signals was attributed to the polymer end groups, while the stronger signals were assigned to the interior CH and CH2 of the polymer chain. The stronger signals were more deshielded than the weaker ones because the interior species are located between two ester fimctionalities.
Furthermore, integrated 'H spectra gave a ratio of double bond hydrogens to methyl protons of 2:3, as expected from the backbone structure. The integrated spectra of P(PF) produced by the previous method showed a ratio of 1:3, verifying loss of polymer unsaturation.
Figure 4(a) shows the 2-D 'H-"C coupled NMR spectrum for 'H region 1.0-1.5 ppm and "C region 15.5-20 ppm. The number 1 corresponds to the methyl functionality labeled in Fig 1. Figure 4(b) shows a 2-D 'H-"C coupled NMR spectrum for'H region 3.0-5.5 ppm and "C region 64-74 ppm. The number 2 corresponds to the propyl methine and 3 corresponds to the propyl methylene of the secondary alcohol functionality labeled in Figure 1, and 5 corresponds to the propyl methine and 6 corresponds to the propyl methylene of the primary alcohol functionality labeled in Figure 1. The label PG-1 refers to methylene from the residual propylene glycol, and the label PG-2 represents methine from the residual propylene glycol. Figure 4(c) shows a 2-D 'H-"C coupled NMR spectrura for 'H region 6.8-7.0 ppm and "C region 127-143 ppm. The number 4 corresponds to the fiunarate double bond atoms as labeled in Figure 1.
Peaks not attributable to P(PF) and due to residual propylene glycol are present at 'H
1.1 ppm and "C 18.8-19.0 ppm for the methyl groups, and at'H 3.3-3.5 and 3.8-3.9 ppm and "C 67.6-68.2 and 68.2-68.6 ppm, respectively, for the methylene and methine groups.
Major byproducts were identified in the NMR spectra of P(PF) produced by the previous synthetic method. Propylene glycol addition across the double bond led to peaks at 46.5 and 71 ppm, while HCl addition produced additional methylene 'H signals at 2.8-3.3 ppm and "C signals at 39-40 ppm and methine ~H signals at 4.6-4.8 ppm and "C
signals at 51-52 ppm. Since no evidence of either of these side products was seen in any of the NMR
spectra collected in the present study, the addition of KZCO, represents a great improvement over the previous synthetic method.
Kinetic studies of the transesterification showed that the molecular weight of a P(PF) reached a final M" of 4900 0700) and M", of 9100 01300) after 16 hours, while the polydispersity index remained below 1.8 throughout the reaction. Thus the P(PF) synthesized by the new method is of higher molecular weight and greater purity than previously prepared material having the same formula. According to two dimensional NMR, the backbone structure of this polymer was as expected and contained no byproducts formed by acid catalyzed addition across the fumarate double bond. It is expected that the present technique will have applicability to P(PF) formation reactions regardless of whether those reactions include the use of a catalyst.
In sum, the present invention provides an efficient and reproducible technique for synthesizing P(PF) having a molecular weight above 4,000 and a low polydispersity index.
This P(PF) is particularly well suited for use in bone cements. A P(PF)-containing composition that is an effective bone cement is described in detail in co-pending Application Serial No. , filed concurrently herewith and entitled Bone Replacement Compound Comprising Poly(Polypropylene Fumarate), which is incorporated by reference herein in its entirety.
While a preferred embodiment has been disclosed and described, it will be understood that certain modifications could be made without departing from the scope of the present invention. For example, the potassium carbonate that serves as an acid neutralizer in the preferred embodiment could be replaced with any suitable proton scavenger, such as but not limited to similar salts, including other allcaline earth and allcali metal carbonates.
As discussed above, the P(PF) made according to the present invention is suitable for use in a replacement compound for living bone. The P(PF) can be incorporated into a paste, along with a monomer capable of addition polymerization an inorganic filler such as beta-tricalcium phosphate, sodium chloride or hydroxyapatite, a radical initiator such as benzoyl peroxide, azobisisobutyronitriie, or acetyl peroxide, and an accelerator such as N,N dimethyl toluidine. Examples of suitable monomer include vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacrylic acid, or 2-hydroxy ethyl methacrylate, and copolymers thereof. While it is preferred that the monomers used are biodegradable, it is contemplated that non-biodegradable monomers such as methyl methacrylate will form only short polymer chains, which, upon degradation of the poly(pmpylene fumarate) backbone, in vivo, will be cleared from a patient's body by normal metabolic processes. Various amounts of the specific ingredients may be combined to produce a useful product. For example, approximately equal 5 amounts of the polypropylene fiimarate), monomer, and filler may be used.
The amounts of each component may be varied according to the desired characteristics of the final composition, as known to one of skill in the art. Likewise, the amount of initiator and accelerator may be varied by one of skill in the art to produce a composite having desired physical characteristics. Preferably, the components are combined in a sterile field, and pass 10 through a moldable putty stage prior to hardening. In addition, by varying the molecular weight of the polypropylene fumarate) a composite material having desired strength and modulus characteristics, including that which approximates the physical characteristics of human trabecular bone, is produced.
IPE~i ~,;~_.~ 5 ~I a V 1,~9' SYNTHESIS OF POLYPROPYLENE FL;m~IARATE) BY ACYLATION OF PROPYLENE GLYCOL
IN THE PRESENCE OF A PROTON SCAVENGER
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of provisional applications Serial No.
60/081,308, filed April 10, 1998 and entitled Synthesis of Poly(Proplyene Fumarate) by Acylation of Propylene Glycol in the Presence of a Proton Scavenger; Serial No. 60/082,182, filed April 16, 1998 and entitled In Vivo Degradation of a Poly(Propylene Fumarate)l ~
Tricalcium. Phosphate Injectable Composite Scaffold; and Serial No.
60/081,405, filed April 10, 1998 and entitled Crosslinking Characteristics of an !nl~ctable Poly(Propylene Fumarate)1~3T'ricalcium Phosphate Past and Mechanical Properties of the Crosslinked Composite for Use as a Biodegradable Bone Cement.
STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT
This work was funded by the National Institutes of Health (RO1-AR44381) (AGM), the National Science Foundation (PSE), and National Institutes of Health Biotechnology Training Grant ST32GM08362.
TECHNICAL FIELD OF THE INVENTION
This invention relates to methods for the synthesis of high molecular weight forms of polypropylene fumarate) having a relatively low polydispersity index. More particularly, the present invention provides methods for synthesizing polypropylene fumarate) having molecular weights above 4,000 and polydispersity indices below 2, and more particularly below 1.8, wherein the high molecular weight polypropylene fumarate) is synthesized in the presence of a proton scavenger.
BACKGROUND OF THE INVENTION
It is often desired to replace or reconstruct all or a portion of a living bone, such as when a bune has been broken or has been resected as a result of a bone tumor.
In these instances, the missing bone can be replaced with a mechanical device, such as a pin, plate or the like, or it can be replaced with an implant that is designed to more closely resemble the original bone itself. Often these implants comprise biodegradable compounds or parts made from such compounds. For example, it is known to provide porous, biodegradable compounds that contain or are coated with an osteogenic substance. It is contemplated that bone tissue will grow back into the pores of the implant and will gradually replace the entire implant as the implant itself is gradually degraded in the in vivo environment.
For obvious reasons, implants, regardless of whether they are biodegradable, should be biocompatible and non-toxic. Furthermore, the steps required for implantation of the implant (eg. the application or generation of heat and the generation of chemical by-products) should also be biocompatible and non-toxic. Also, the techniques and time periods required for implantation should be suited to the surgical environment.
Under current practices, bone implants are typically formed from a substance that is initially malleable and then becomes hard after a reasonably short period of time. Because living bone tends to atrophy and degrade in the absence of compressive stress, however, it is important that the implant not become too hard. An implant whose compressive strength is too great (i.e. an implant that is too hard) will cause stress shielding of the surrounding bone.
Stress shielding in taro causes the surrounding bone to weaken and may ultimately result in catastrophic failure. Hence, the suitability of a given substance for implantation as a bone replacement depends on its biocompatibility, set time, biodegradability and ultimate compressive strength. Certain polymers have been found to be suitable in this regard.
Polypropylene fumarate) (hereinafter "P(PF)'~ is one such substance. P(PF) is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are cleared from the human body by normal metabolic processes. Although P(PF) is a known polymer, its routine, reproducible synthesis and the synthesis of high molecular weight forms and forms with low polydispersity indices have not previously been successfully accomplished. Known methods for the synthesis of P(PF), for example by equilibrium polycondensation, utilize reactions that are difficult to control. These synthetic methods typically require extremely high heat, the presence of a catalyst, and/or long reaction times.
Nevertheless, the fumarate double bonds in P(PF) are reactive and crosslink at low temperatures, making it valuable as an in situ polymerizable biomaterial. An effective composite mixture incorporating P(PF), a crosslinking monomer (N vinyl pyrrolidinone), a porogen (sodium chloride), and a particulate phase ((3-tricalcium phosphate) can be injected into skeletal defects of irregular shape or size. As is known in the art, the mechanical properties of the cured material can be tailored by altering the ratios of the porogen and particulate phase, as well as the monomer to polymer ratio.
The maximum molecular weight MW of the P(PF) polymer that has heretofore been reasonably achievable without encountering an unacceptably high polydispersity index is limited to less than 3,000. P(PF) polymers have been produced having MW above 3,000, but because the degree of cross-linking varies greatly within the specimen, the polydispersity indices, (the ratio of weight average molecular weight to number average molecular weight), for these polymers are well above 2Ø Premature crosslinking of the polymer often limits the linear size or molecular weight of the linear polymer that can be achieved. It is believed that this is in part due to the fact that some of the fumarate double bonds are reaction sites for the acid-catalyzed addition of various other groups. The presence of these groups and the corresponding elimination of the double bond reduces the degree of unsaturation and thus limits molecular weight. Early attempts to mitigate this effect and increase the weight average molecular weight entailed the use of an amine to neutralize the acid, but results of this reaction were undesirable. Other early attempts included the use of buffers, and several other materials also proved ineffective.
Hence, it is highly desirable to provide an efficient, controlled synthetic reaction whereby high molecular weight linear polypropylene fumarate) having a relatively low polydispersity index can reproducibly synthesized without regardless of whether an acid catalyst is used.
BRIEF SLrMMARY OF THE INVENTION
The present invention provides a method for making high molecular weight linear poiy(pmpylene fumarate) having a relatively low polydispersity index by utilizing a relatively pure intermediate. According to the present invention, fumaryi chloride and propylene glycol are reacted in the presence of potassium carbonate, which serves as a proton scavenger, to produce bis(propyl fumarate). The reaction of fumaryl chloride and propylene glycol also produces HCI. The potassium carbonate present in the reaction solution reacts with the HCI
to give water and COZ and prevents the acid from catalyzing reactions at the fumarate double bond. According to a prefer ed embodiment, a mole ratio of KZCO, to fumaryl chloride of between approximately 1.2:1 and 3:1 is used. The bis(propyl fumarate) produced according to this technique can be transesterified using conventional processing steps to yield P(PF).
The P(PF) produced from bis(propyl fumarate) produced according to the present method has a higher molecular weight and is purer than P(PF) produced using previously known techniques.
BRIEF DESCRIPTION OF THE DRAWINGS
For an introduction to the detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying Figures, wherein:
Figure 1 is a labeled chemical structure of polypropylene fiunarate);
Figure 2 is a two-step reaction scheme for the formation of polypropylene fumarate) from propylene glycol and fumaryl chloride;
Figure 3 is an FTIR spectra of polypropylene fumarate) following transesterification and of the short chain oligomer prior to transesterification; and Figures 4A-C are a series of NMR spectra confirming the structure illustrated in Figure 1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It has been discovered that the P(PF)s formed according to the preferred embodiment have greater molecular weights than those produced by previously known reaction methods without requiring the use of a catalyst. Equally importantly, the preferred method yields P(PF)s having polydispersity indices, or PI (PI = Mw / M" where MW is the weight average molecular weight and Mn is the number average molecular weight), less than 2 and more preferably approximately 1.
Referring initially to Figure 1, the chemical structure for the desired reaction product P(PF) is shown and various functional groups are labeled 1-6. The structure depicted in Figure 1 is confirmed by the peaks labeled correspondingly 1-6 in Figures 4A-C, as described in detail below. According to the present invention, P(PF)" for which n equals at least 10 and more preferably at least 14, can be manufactured consistently and with a relatively high polydispersity index in a two-step process. The first step includes acylation of propylene glycol with fumaryl chloride in the presence of a proton scavenger. As generally disclosed in U.S. Patent 5,733,951, which is incorporated herein in its entirety, the acylation step releases 2HCl, which results in a lowering of the pH of the reaction solution. In prior art processes, the presence of the acid allowed the acid-catalyzed addition of various other groups, such as excess propylene glycol, at the fumarate double bond. These undesired side reactions reduced the purity of the desired bis(propyl fumarate) intermediate and thus increased the polydispersity index and reduced the maximum molecular weight of the ultimate P(PF) product that can be obtained.
It has been discovered that the addition of potassium carbonate to the reaction solution effectively neutralizes the acid and prevents premature loss of the fumarate double bond. The 5 potassium carbonate is preferably added in molar excess, to ensure that the acid catalysis of bonding across the double bonds is minimized. This process produces a low molecular weight oligomer, bis(propyl fumarate), which can then be transesterified according to lc~own techniques.
As shown in Figure 2, the formation of PPF is a two-step reaction process. The first step involves forming a short chain oligomer from fumaryl chloride and propylene glycol in the presence of potassium carbonate. This is followed by a transesterifieation step to form the high molecular weight polymer, PPF. The specifics of each reaction are described below.
Ezample 1 Materials Fumaryl chloride (Acros, Pittsburgh, PA) was purified by distillation at 159-161 °C. Propylene glycol was also obtained from Acros and used as received. Anhydrous potassium carbonate (Fisher, Pittsburgh, PA) was ground into a fine powder with a mortar and pestle. The solvents for polymer purification were purchased from Fisher as reagent grade and used as received.
Oligomer preparation. Fumaryl chloride, propylene glycol, and potassium carbonate were measured out in a 1:3:1.5 molar ratio. The propylene glycol was dissolved in chloroform (1:2 by volume) and placed in a 2 L-3 neck flask along with the powdered potassium carbonate.
This mixture was stirred with an overhead mechanical stirrer to form a slurry.
Fumaryl chloride dissolved in chloroform ( 1:1 volume ratio) was added dropwise to the slurry. The reaction mixture was maintained at room temperature (by altering the rate of the fumaryl chloride addition) under a nitrogen blanket. Additional chloroform was added as needed to facilitate stirring. Upon completion of the fumaryl chloride addition, the mixture was transferred to 50 mL centrifuge tubes and spun down for 15 minutes at 4000 rpm until the potassium carbonate was completely removed. The supernatant was then added dropwise to petroleum ether to force the oligomer out of solution, and the precipitate was rotary-evaporated to yield an amber-colored oil.
Transesterification. The oligomer was transferred to a 1 L-3 neck reaction vessel suspended in an oil bath. The bath temperature was raised to 160°C and the system was evacuated to a pressure of 100-110 mm Hg. Nitrogen was passed through a coil in the oil bath for preheating and subsequently bubbled into the bottom of the reaction vessel to facilitate mixing and maintain an inert environment. Propylene glycol was liberated by the formation of each O-CO bond during the transesterification and was condensed as a byproduct.
Samples for kinetic analysis of the molecular weight progression were removed each hour during the reaction. Upon termination of the transesterification, the vessel was pressurized to 1 arm and the product was allowed to cool. This product was dissolved in chloroform and precipitated through dropwise addition of the mixture to petroleum ether with stirring. The precipitate was rotary-evaporated for 2 hours. The final product, PPF, was a much darker color and of a greater viscosity when compared to PPF synthesized in the absence of potassium carbonate. Moreover, the transesterification reaction no longer catalytic antimony trioxide, an undesirable compound for in vivo applications. For the polymer characterization described below, PPF prepared fiom a 16 hour transesterification with a number average molecular weight of approximately 5000 Da was used.
Polymer Characterization.
FTTR Fourier transform infrared spectra were obtained on a Nicolet 500 spectrometer (Madison, W17. Samples were placed on a zinc selenide attenuated total reflection crystal for analysis. A total of 32 scans was collected at a 4 crri' resolution. The peak at 2300 crri ' is due to the presence of carbon dioxide in the sampling chamber.
NMR Nuclear magnetic resonance spectra were obtained on a Broker 500 MHz spectrometer (Switzerland). 'H, Distortionless Enhancement by Polarization Transfer-135 "C
(DEPT-135 "C), and 2D 'H-"C chemical shift correlation spectra of PPF were acquired using standard pulse programs.
MS Mass spectral data of the oligomer and high molecular weight polymer were obtained in fast-atom bombardment (FAB) mode on a Finnigan MAT 95 spectrometer (New York, NY) using a Cs ion gun. Nitrobenzyl alcohol was used as a matrix.
GPC Gel permeation chromatography was used to determine polymer molecular weight distributions through the application of a differential refractometer detector (Waters, Model 410, Milford, MA). A Phenogel guard column (50x7.8 mm, 5 gym, mixed bed, Phenomenex, Tomance, CA) and a Phenogel column (300x7.8 mm, S~m, mixed bed, Phenomenex) were used to elute the samples at 1 mL,/min chloroform flow rate. Polystyrene standards were used to obtain a calibration curve for calculating the polymer molecular weights.
Samples were analyzed for four transesterification reactions, each spanning a 16 hour time fi~ame.
Results FTIR Carbonyl stretching at 1714 ctrl', C=C stretching at 1640 cm'', and methylene scissoring and asymmetric bending at 1457 cm' were all evident in the FTIR
spectra of the oligomer and final polymer (Figure 3). C-O stretching at 1266 ctrl', methyl symmetric bending at 1382 crri', and the C-H bend of the double bond at 983 crri' were also present in both spectra. The oligomer had a more intense OH stretch at 3340 ciri' than the higher molecular weight polymer due to the greater number of hydroxyl end groups in the short chain oligomer. The relative intensity of the hydroxyl peak decreased with increasing molecular weight of the samples taken throughout the transesterificadon. No major differences were identified in the FTIR spectra of the PPF formed through the new reaction pathway as opposed to the previous method.
NMR Through the combination of proton, carbon, and two-dimensional proton-carbon chemical shift correlation spectra, the PPF chemical structure represented in Figure 1 was verified. Contour positions for all pertinent functional groups represented in this structure are given in Table 1 and shown in Figures 4(a)-(c).
Table 1. Identification of Functional Group Contours From the 2-d Proton-Carbon Correlation NMR Spectra.
Functional Figure LabelProton (ppm)Carbon (ppm)DEPT Peak Group Propyl methyl 1 1.15-1.51 16.05-19.4 Methyl Propyl methine2 4.08-4.11 65.2 Methine of 2 alcohol Pmpyl methylene3 4.03-4.17 69.8-70.1 Methylene of 2 alcohol Olefinic bonds4 6.85-6.93 132.9-134.4no contour propyl methine5 5.0-5.12 72.4-73.1 Methine of 1 alcohol propyl methylene6 3.57-3.69 64.7 Methyiene of 1 alcohol not shown - 165.0-171.8no contour The peak assignments are based on calculated proton and carbon chemical shifts found from the tabulated values in Silverstein et al.~~ Acylation of propylene glycol to leave a primary alcohol resulted in a methylene peak (6) with signals at 'H 3.57-3.69 and "C
64.7 and a methine peak (5) with signals at'H 5.0-5.12 and "C 72.4-73.1. Acylation of propylene glycol to leave a secondary alcohol resulted in a methylene peak (3) with signals at'H 4.03-4.17 and "C 69.8-70.1 and a methine peak (2) with signals at 'H 4.08-4.1 l and "C 65.2.
The spectra of the short chain oligomer and the higher molecular weight polymer were investigated to confirm these peak assignments. The secondary alcohol methylene (3) and primary alcohol methine (5) each produced two signals. The signals within each pair were of approximately the same intensity in the oligomer spectrum. However, in the high molecular weight polymer spectrum, one signal from each pair was more intense. The weaker of the two signals was attributed to the polymer end groups, while the stronger signals were assigned to the interior CH and CH2 of the polymer chain. The stronger signals were more deshielded than the weaker ones because the interior species are located between two ester fimctionalities.
Furthermore, integrated 'H spectra gave a ratio of double bond hydrogens to methyl protons of 2:3, as expected from the backbone structure. The integrated spectra of P(PF) produced by the previous method showed a ratio of 1:3, verifying loss of polymer unsaturation.
Figure 4(a) shows the 2-D 'H-"C coupled NMR spectrum for 'H region 1.0-1.5 ppm and "C region 15.5-20 ppm. The number 1 corresponds to the methyl functionality labeled in Fig 1. Figure 4(b) shows a 2-D 'H-"C coupled NMR spectrum for'H region 3.0-5.5 ppm and "C region 64-74 ppm. The number 2 corresponds to the propyl methine and 3 corresponds to the propyl methylene of the secondary alcohol functionality labeled in Figure 1, and 5 corresponds to the propyl methine and 6 corresponds to the propyl methylene of the primary alcohol functionality labeled in Figure 1. The label PG-1 refers to methylene from the residual propylene glycol, and the label PG-2 represents methine from the residual propylene glycol. Figure 4(c) shows a 2-D 'H-"C coupled NMR spectrura for 'H region 6.8-7.0 ppm and "C region 127-143 ppm. The number 4 corresponds to the fiunarate double bond atoms as labeled in Figure 1.
Peaks not attributable to P(PF) and due to residual propylene glycol are present at 'H
1.1 ppm and "C 18.8-19.0 ppm for the methyl groups, and at'H 3.3-3.5 and 3.8-3.9 ppm and "C 67.6-68.2 and 68.2-68.6 ppm, respectively, for the methylene and methine groups.
Major byproducts were identified in the NMR spectra of P(PF) produced by the previous synthetic method. Propylene glycol addition across the double bond led to peaks at 46.5 and 71 ppm, while HCl addition produced additional methylene 'H signals at 2.8-3.3 ppm and "C signals at 39-40 ppm and methine ~H signals at 4.6-4.8 ppm and "C
signals at 51-52 ppm. Since no evidence of either of these side products was seen in any of the NMR
spectra collected in the present study, the addition of KZCO, represents a great improvement over the previous synthetic method.
Kinetic studies of the transesterification showed that the molecular weight of a P(PF) reached a final M" of 4900 0700) and M", of 9100 01300) after 16 hours, while the polydispersity index remained below 1.8 throughout the reaction. Thus the P(PF) synthesized by the new method is of higher molecular weight and greater purity than previously prepared material having the same formula. According to two dimensional NMR, the backbone structure of this polymer was as expected and contained no byproducts formed by acid catalyzed addition across the fumarate double bond. It is expected that the present technique will have applicability to P(PF) formation reactions regardless of whether those reactions include the use of a catalyst.
In sum, the present invention provides an efficient and reproducible technique for synthesizing P(PF) having a molecular weight above 4,000 and a low polydispersity index.
This P(PF) is particularly well suited for use in bone cements. A P(PF)-containing composition that is an effective bone cement is described in detail in co-pending Application Serial No. , filed concurrently herewith and entitled Bone Replacement Compound Comprising Poly(Polypropylene Fumarate), which is incorporated by reference herein in its entirety.
While a preferred embodiment has been disclosed and described, it will be understood that certain modifications could be made without departing from the scope of the present invention. For example, the potassium carbonate that serves as an acid neutralizer in the preferred embodiment could be replaced with any suitable proton scavenger, such as but not limited to similar salts, including other allcaline earth and allcali metal carbonates.
As discussed above, the P(PF) made according to the present invention is suitable for use in a replacement compound for living bone. The P(PF) can be incorporated into a paste, along with a monomer capable of addition polymerization an inorganic filler such as beta-tricalcium phosphate, sodium chloride or hydroxyapatite, a radical initiator such as benzoyl peroxide, azobisisobutyronitriie, or acetyl peroxide, and an accelerator such as N,N dimethyl toluidine. Examples of suitable monomer include vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacrylic acid, or 2-hydroxy ethyl methacrylate, and copolymers thereof. While it is preferred that the monomers used are biodegradable, it is contemplated that non-biodegradable monomers such as methyl methacrylate will form only short polymer chains, which, upon degradation of the poly(pmpylene fumarate) backbone, in vivo, will be cleared from a patient's body by normal metabolic processes. Various amounts of the specific ingredients may be combined to produce a useful product. For example, approximately equal 5 amounts of the polypropylene fiimarate), monomer, and filler may be used.
The amounts of each component may be varied according to the desired characteristics of the final composition, as known to one of skill in the art. Likewise, the amount of initiator and accelerator may be varied by one of skill in the art to produce a composite having desired physical characteristics. Preferably, the components are combined in a sterile field, and pass 10 through a moldable putty stage prior to hardening. In addition, by varying the molecular weight of the polypropylene fumarate) a composite material having desired strength and modulus characteristics, including that which approximates the physical characteristics of human trabecular bone, is produced.
Claims (22)
1. Poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2Ø
2. Poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2Ø
3. A method for synthesizing poly(polypropylene fumarate), comprising:
(a) reacting fumaryl chloride to form bis(hydroxypropyl fumarate); and (b) transesterifying the bis(hydroxypropyl fumarate);
wherein step (a) is carried out in the presence of a proton scavenger.
(a) reacting fumaryl chloride to form bis(hydroxypropyl fumarate); and (b) transesterifying the bis(hydroxypropyl fumarate);
wherein step (a) is carried out in the presence of a proton scavenger.
4. The method of claim 3 wherein the proton scavenger is selected from the group comprising amines, buffers and carbonate salts.
5. The method of claim 3 wherein the proton scavenger is selected from the group comprising alkali metal carbonates and alkaline-earth metal carbonates.
6. The method of claim 3 wherein the proton scavenger is potassium carbonate.
7. The method of claim 3 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2Ø
8. The method of claim 3 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2Ø
9. A composition suitable for use in orthopedic applications, comprising:
poly(propylene fumarate);
a monomer capable of addition polymerization;
an inorganic filler; and a radical initiator; and wherein said poly(propylene fumarate) has a weight average molecular weight above 5,000 and a polydispersity index below 2Ø
poly(propylene fumarate);
a monomer capable of addition polymerization;
an inorganic filler; and a radical initiator; and wherein said poly(propylene fumarate) has a weight average molecular weight above 5,000 and a polydispersity index below 2Ø
10. The composition according to claim 9 wherein said monomer is selected from the group consisting of vinyl pyrrolidone, acrylic acid, methyl methacrylate, styrene, methacrylic acid, 2-hydroxy ethyl methacrylate, and copolymers thereof.
11. The composition according to claim 9 wherein said inorganic filler is selected from the group consisting of beta-tricalcium phosphate, sodium chloride, hydroxyapatite and combinations thereof.
12. The composition according to claim 9 wherein said radical initiator is selected from the group consisting of such as benzoyl peroxide, azobisisobutyronitrile, and acetyl peroxide.
13. The composition according to claim 9 wherein said poly(propylene fumarate) has a weight average molecular weight above 9,000 and a polydispersity index below 2Ø
14. The composition according to claim 13 wherein said composition includes an amount of cross linking agent between about 0.25 ml per gram of P{PF) and about 0.5 ml per gram of P(PF).
15. The composition according to claim 13 wherein said composition includes an amount of initiator between about 0.001 grams per gram of P(PF) and about 0.005 grams per gram of P(PF).
16. The composition according to claim 13, further including an accelerator.
17. A method for synthesizing poly(polypropylene fumarate), comprising:
(a) reacting fumaryl chloride to form bis{hydroxypropyl fumarate);
(b) transesterifying the bis(hydroxypropyl fumarate); and (c) substantially maintaining the unsaturation of the fumarate.
(a) reacting fumaryl chloride to form bis{hydroxypropyl fumarate);
(b) transesterifying the bis(hydroxypropyl fumarate); and (c) substantially maintaining the unsaturation of the fumarate.
18. The method of claim 16, including the step of carrying out step (a) in the presence of a proton scavenger.
19. The method of claim 17 wherein the proton scavenger is selected from the group comprising alkali metal carbonates and alkaline-earth metal carbonates.
20. The method of claim 18 wherein the proton scavenger is potassium carbonate.
21. The method of claim 16 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 5,000 and a polydispersity index below 2Ø
22. The method of claim 16 wherein step (b) produces poly(polypropylene fumarate) having a weight average molecular weight above 9,000 and a polydispersity index below 2Ø
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8130898P | 1998-04-10 | 1998-04-10 | |
US8140598P | 1998-04-10 | 1998-04-10 | |
US60/081,405 | 1998-04-10 | ||
US60/081,308 | 1998-04-10 | ||
US8218298P | 1998-04-16 | 1998-04-16 | |
US60/082,182 | 1998-04-16 | ||
PCT/US1999/007912 WO1999052469A1 (en) | 1998-04-10 | 1999-04-09 | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2327730A1 true CA2327730A1 (en) | 1999-10-21 |
Family
ID=27373944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002327730A Abandoned CA2327730A1 (en) | 1998-04-10 | 1999-04-09 | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
Country Status (7)
Country | Link |
---|---|
US (2) | US6124373A (en) |
EP (1) | EP1079869B1 (en) |
JP (1) | JP2002539275A (en) |
AT (1) | ATE291444T1 (en) |
CA (1) | CA2327730A1 (en) |
DE (1) | DE69924369D1 (en) |
WO (1) | WO1999052469A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486232B1 (en) * | 1997-04-18 | 2002-11-26 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for internal fixation devices and bone cements |
CA2327730A1 (en) | 1998-04-10 | 1999-10-21 | Wm Marsh Rice University | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
CA2370330C (en) * | 1999-04-16 | 2009-01-20 | Wm. Marsh Rice University | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers |
US6884778B2 (en) * | 2000-04-14 | 2005-04-26 | William Marsh Rice University | Biocompatible macromers |
DE10032220A1 (en) * | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium ammonium phosphate cements, their manufacture and use |
AU2002305201A1 (en) * | 2001-04-19 | 2002-11-05 | Case Western Reserve University | Fabrication of a polymeric prosthetic implant |
CA2451203A1 (en) * | 2001-06-28 | 2003-01-09 | Wm. Marsh Rice University | Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials |
US7629388B2 (en) | 2001-11-20 | 2009-12-08 | William Marsh Rice University | Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion |
US20030180344A1 (en) * | 2002-02-05 | 2003-09-25 | Cambridge Scientific, Inc. | Bioresorbable osteoconductive compositions for bone regeneration |
US6884432B2 (en) * | 2002-04-25 | 2005-04-26 | Mayo Foundation For Medical Education And Research | Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery |
US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
US20070065652A1 (en) * | 2003-03-13 | 2007-03-22 | Willaim Marsh Rice University | Composite injectable and pre-fabricated bone replacement material and method for the production of such bone replacement material |
US20060264967A1 (en) | 2003-03-14 | 2006-11-23 | Ferreyro Roque H | Hydraulic device for the injection of bone cement in percutaneous vertebroplasty |
US8066713B2 (en) | 2003-03-31 | 2011-11-29 | Depuy Spine, Inc. | Remotely-activated vertebroplasty injection device |
US8415407B2 (en) | 2004-03-21 | 2013-04-09 | Depuy Spine, Inc. | Methods, materials, and apparatus for treating bone and other tissue |
WO2006011152A2 (en) * | 2004-06-17 | 2006-02-02 | Disc-O-Tech Medical Technologies, Ltd. | Methods for treating bone and other tissue |
WO2005004811A2 (en) * | 2003-07-01 | 2005-01-20 | Mayo Foundation For Medical Education And Research | Self-crosslinkable poly(caprolactone fumarate) |
US7252686B2 (en) * | 2003-08-13 | 2007-08-07 | Boston Scientific Scimed | Methods for reducing bone compression fractures using wedges |
US8579908B2 (en) | 2003-09-26 | 2013-11-12 | DePuy Synthes Products, LLC. | Device for delivering viscous material |
US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
ES2396133T3 (en) | 2004-04-27 | 2013-02-19 | Kyphon SÀRl | Bone replacement compositions and method of use |
US9255178B2 (en) * | 2004-11-12 | 2016-02-09 | Mayo Foundation For Medical Education And Research | Photocrosslinkable poly (caprolactone fumarate) |
EP1812481B1 (en) * | 2004-11-18 | 2012-01-11 | Mayo Foundation for Medical Education and Research | Block copolymers of polycaprolactone and poly (propylene fumarate) |
ATE511439T1 (en) * | 2005-04-29 | 2011-06-15 | Mayo Foundation | HYDROPHILIC/HYDROPHOBIC POLYMER NETWORK BASED ON POLY(CAPROLACTONE FUMARATE), POLY(ETHYLENE GLYCOLFUMARATE) AND COPOLYMERS THEREOF |
US9381024B2 (en) | 2005-07-31 | 2016-07-05 | DePuy Synthes Products, Inc. | Marked tools |
US9918767B2 (en) | 2005-08-01 | 2018-03-20 | DePuy Synthes Products, Inc. | Temperature control system |
US7651701B2 (en) * | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
US8360629B2 (en) | 2005-11-22 | 2013-01-29 | Depuy Spine, Inc. | Mixing apparatus having central and planetary mixing elements |
US7754005B2 (en) * | 2006-05-02 | 2010-07-13 | Kyphon Sarl | Bone cement compositions comprising an indicator agent and related methods thereof |
US7507286B2 (en) * | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
WO2008001385A2 (en) * | 2006-06-29 | 2008-01-03 | Depuy Spine, Inc. | Integrated bone biopsy and therapy apparatus |
US9642932B2 (en) | 2006-09-14 | 2017-05-09 | DePuy Synthes Products, Inc. | Bone cement and methods of use thereof |
WO2008039382A2 (en) * | 2006-09-21 | 2008-04-03 | Kyphon Sarl | Diammonium phosphate and other ammonium salts and their use in preventing clotting |
WO2008047371A2 (en) | 2006-10-19 | 2008-04-24 | Depuy Spine, Inc. | Fluid delivery system |
WO2008073190A2 (en) * | 2006-11-03 | 2008-06-19 | Kyphon Sarl | Materials and methods and systems for delivering localized medical treatments |
EP2022446B1 (en) * | 2007-07-30 | 2012-04-04 | Purzer Pharmaceutical Co., Ltd. | Bio-degenerable bone cement and manufacturing method thereof |
US20090286907A1 (en) * | 2008-01-23 | 2009-11-19 | Beltz Mark W | Fumaric Acid/Diol Polyesters and Their Manufacture and Use |
US7968616B2 (en) * | 2008-04-22 | 2011-06-28 | Kyphon Sarl | Bone cement composition and method |
EP2590605A1 (en) | 2010-07-09 | 2013-05-15 | Board of Regents of the University of Texas System | Biodegradable scaffolds |
US11865785B2 (en) * | 2010-08-20 | 2024-01-09 | H. David Dean | Continuous digital light processing additive manufacturing of implants |
CN103379924B (en) | 2010-08-20 | 2015-07-29 | 凯斯西储大学 | Manufacture is added in the continuous number optical processing of implant |
AU2015257289B2 (en) | 2014-05-05 | 2020-10-01 | Advanced Medical Solutions Israel (Sealantis) Ltd | Biological adhesives and sealants and methods of using the same |
CA2967949C (en) | 2014-11-18 | 2023-04-04 | The University Of Akron | Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof |
JP2020506990A (en) | 2017-02-02 | 2020-03-05 | アクロン大学 | Functionalized poly (propylene fumarate) polymer prepared by ring-opening polymerization using magnesium catalyst |
GB2594243A (en) * | 2020-04-15 | 2021-10-27 | Arterius Ltd | A bone cement |
EP4181924A1 (en) * | 2020-07-15 | 2023-05-24 | The University of Akron | Synthesis of poly (propylene maleate-co-succinate) by the time-dependent reduction of poly (propylene maleate) double bonds mediated by zinc and acetic acid |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3701748A (en) | 1966-07-20 | 1972-10-31 | Rohm & Haas | Unsaturated polyester resinous compositions |
GB1225803A (en) * | 1967-06-02 | 1971-03-24 | ||
US5286763A (en) * | 1983-03-22 | 1994-02-15 | Massachusetts Institute Of Technology | Bioerodible polymers for drug delivery in bone |
US4722948A (en) * | 1984-03-16 | 1988-02-02 | Dynatech Corporation | Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone |
US5989579A (en) | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
US4843112A (en) * | 1987-03-12 | 1989-06-27 | The Beth Israel Hospital Association | Bioerodable implant composition |
US4888413A (en) | 1988-01-11 | 1989-12-19 | Domb Abraham J | Poly(propylene glycol fumarate) compositions for biomedical applications |
AU639645B2 (en) | 1989-10-10 | 1993-07-29 | Wm. Wrigley Jr. Company | Gradual release structures made from fiber spinning techniques |
FR2661682B1 (en) | 1990-05-04 | 1993-12-10 | Norsolor | NEW RESINOUS COMPOSITIONS BASED ON UNSATURATED POLYESTER RESINS AND NEW ANTI-SHRINKAGE ADDITIVES. |
ES2153378T3 (en) | 1992-02-28 | 2001-03-01 | Univ Texas | PHOTOPOLIMERIZABLE BIODEGRADABLE HYDROGELS AS FABRIC CONTACT MATERIALS AND CONTROLLED DISCHARGE CARRIER. |
US5733951A (en) * | 1994-04-28 | 1998-03-31 | Yaszemski; Michael J. | Poly(propylene fumarate) |
US5527864A (en) * | 1995-08-08 | 1996-06-18 | Suggs; Laura J. | Poly(propylene fumarate-co-ethylene oxide) |
DE69615811T2 (en) | 1995-12-25 | 2002-04-04 | Sharp Kk | imaging system |
US5998362A (en) | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
US5854382A (en) | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
CA2327730A1 (en) | 1998-04-10 | 1999-10-21 | Wm Marsh Rice University | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
-
1999
- 1999-04-09 CA CA002327730A patent/CA2327730A1/en not_active Abandoned
- 1999-04-09 WO PCT/US1999/007912 patent/WO1999052469A1/en active IP Right Grant
- 1999-04-09 EP EP99915349A patent/EP1079869B1/en not_active Expired - Lifetime
- 1999-04-09 US US09/289,361 patent/US6124373A/en not_active Expired - Lifetime
- 1999-04-09 AT AT99915349T patent/ATE291444T1/en not_active IP Right Cessation
- 1999-04-09 JP JP2000543082A patent/JP2002539275A/en active Pending
- 1999-04-09 DE DE69924369T patent/DE69924369D1/en not_active Expired - Fee Related
-
2000
- 2000-10-04 US US09/678,816 patent/US6355755B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6355755B1 (en) | 2002-03-12 |
WO1999052469A9 (en) | 2000-03-23 |
EP1079869A1 (en) | 2001-03-07 |
EP1079869A4 (en) | 2002-08-07 |
JP2002539275A (en) | 2002-11-19 |
ATE291444T1 (en) | 2005-04-15 |
DE69924369D1 (en) | 2005-04-28 |
WO1999052469A1 (en) | 1999-10-21 |
US6124373A (en) | 2000-09-26 |
EP1079869B1 (en) | 2005-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6355755B1 (en) | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger | |
KR100696407B1 (en) | Biodegradable polypropylene fumarate networks cross linked with polypropylene fumarate-diacrylate macromers | |
JP3161729B2 (en) | Method for producing medically applicable article from copolymer of lactide and ε-caprolactone | |
US10844158B2 (en) | Chain extenders | |
JP3481762B2 (en) | Poly (alkylene diglycolate) s, copolymers, blends, their production methods and medical devices using them | |
Kharas et al. | Synthesis and characterization of fumarate‐based polyesters for use in bioresorbable bone cement composites | |
EP1267953B1 (en) | Compositions of crosslinkable prepolymers for biodegradable implants | |
JP2986509B2 (en) | Modified polyester resin composition, method for producing the same, and use thereof | |
US5688900A (en) | Absorbable polyalkylene diglycolates | |
JP5527968B2 (en) | Hydrophilic / hydrophobic polymer networks based on poly (caprolactone fumarate), poly (ethylene glycol fumarate) and copolymers thereof | |
EP0617712B1 (en) | Copolymer of lactone and carbonate and process for the preparation of such a copolymer | |
CN111053951A (en) | Elastic degradable 3D printing porous scaffold and preparation method thereof | |
Peter et al. | Poly (propylene fumarate) | |
US6602963B2 (en) | Polyesters containing (meth)acrylate end groups | |
KR102614952B1 (en) | Moldable shape memory polymer-based dental membrane and its manufacturing method | |
AU2006294414B2 (en) | Chain extenders | |
AU2005219452B2 (en) | Biocompatible polymer compositions for dual or multistaged curing | |
CN112646142A (en) | Copolymer, method for producing copolymer, and surgical instrument | |
Ho | Injectable biodegradable poly (ester-co-ether) methacrylate monomers for bone tissue engineering and drug delivery applications | |
Herath | Synthesis and characterization of novel biodegradable crosslinked polyesters | |
MXPA97003652A (en) | Absalbib polyalykylene diglycollates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |